



BLA 125514/S-128

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Attention: Siyoung Ahn
Senior Director, Global Regulatory Affairs
126 E. Lincoln Avenue, P.O. Box 2000, B295
Rahway, NJ 07065

Dear Ms. Ahn:

Please refer to your supplemental biologics license application (sBLA), dated March 29, 2022, received March 29, 2022, and your amendments, submitted under section 351(a) of the Public Health Service Act for Keytruda (pembrolizumab) injection.

This Prior Approval sBLA provides for the following new indication:

Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a \geq 4 cm), II, or IIIA non-small cell lung cancer.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) and include the labeling changes proposed in any pending

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

“Changes Being Effectuated” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

- 4396-1 Complete EORTC/ETOP Study 1419 (KEYNOTE-091/PEARLS; NCT02504372) to further characterize the clinical benefit of pembrolizumab as adjuvant treatment following resection with or without platinum-based chemotherapy for adult patients with non-small cell lung cancer. Provide all planned analyses for interim analysis 3, including final disease-free survival for the PD-L1 TPS $\geq 50\%$ population and interim overall survival in the intention-to-treat (ITT) population and in the population of patients with PD-L1 TPS $\geq 50\%$. Additionally, provide the final analyses of Overall Survival in the ITT population and in the

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

population of patients with PD-L1 TPS $\geq 50\%$.

The timetable you submitted on January 17, 2023, states that you will conduct this study according to the following schedule:

Trial Completion: 01/2026

Final Report Submission: 07/2026

Submit the datasets with the final report submission.

Submit clinical protocols to your IND 116833 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled **“Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,”** or **“Postmarketing Commitment Correspondence.”**

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, contact Emily Pak, PharmD, Regulatory Health Project Manager at Emily.Pak@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Harpreet Singh, MD
Director
Division of Oncology 2
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BONNIE HARPREET MOORE
01/26/2023 02:25:39 PM